Modufolin® is a folate-based bio-modulator designed to replace leucovorin/levoleucovorin as the preferred treatment to enhance the activity and reduce associated toxicity of the widely used cancer chemotherapeutic agent 5-FU (5-flluorouracil). It is currently being evaluated in three Phase I/II studies, two in colorectal cancer and one in osteosarcoma. Read more about Modufolin
Although several modern chemo drugs have been introduced that dramatically improve the treatment of many cancer diseases, they show limited effect in treating solid tumors. 5-FU and leucovorin/levoleucovorin is still the core treatment used today for colorectal cancer and Modufolin® has the potential to enable 5-FU to work more effectively.
Click the link below to find out whats new at Isofol Medical:
Click the link below to stay informed about our progress.
To find out the latest news about our ongoing clinical phase II trial please go to:
News & Press information
Isofol Medical present at Aktietorget investor meeting
Isofol Medical AB presented at the AktieTorget investor meeting on Wednesday, October 5. This was a meeting arranged by SvD Business and AktieTorget. The presentation was made in conjunction with Yield Life Science AB, one of the major owners of Isofol Medical.
Isofol Medical has successfully advanced to the next dose level of Modufolin® in a phase I/II clinical trial in colorectal cancer.
Isofol Medical AB today announced initiation of the next dose level of Modufolin®, in combination with 5-FU and oxaliplatin or 5-FU and irinotecan, in the ongoing, incremental dose cohort, phase I/II clinical trial, ISO-CC-005. In total 16 patients with stage IV colorectal cancer have successfully completed their treatment with Modufolin® at 30 mg/m2. Isofol has now initiated a second dose level of Modufolin®, 60mg/m2, in combination with 5-FU and oxaliplatin or 5-FU and irinotecan. This is a safety study evaluating four different doses of Modufolin® with the intention to identify the dose with most favourable tolerability.